{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(31)"],"submitter":["Jorgensen AM"],"funding":["Nachwuchsförderung der Universität Innsbruck/Support Program for Junior Scientists at the University of Innsbruck"],"pubmed_abstract":["Alternative methods to hydrophobic ion pairing for the formation of lipophilic complexes of peptide drugs to incorporate them in lipid-based nanocarriers such as self-emulsifying drug delivery systems (SEDDS) for oral administration are highly on demand. Such an alternative might be reverse micelles. Within this study, SEDDS containing dry reverse micelles (dRMs<sub>PMB</sub> ) formed with an anionic (sodium docusate; AOT), cationic (dimethyl-dioctadecyl-ammonium bromide; DODAB), amphoteric (soy lecithin; SL), or non-ionic (polysorbate 85; P85) surfactant loaded with the model peptide drug polymyxin B (PMB) are developed. They are characterized regarding size, payload, release kinetics, cellular uptake, and peptide activity. SEDDS exhibit sizes from 22.2 ± 1.7 (AOT-SEDDS-dRMs<sub>PMB</sub> ) to 61.7 ± 3.2 nm (P85-SEDDS-dRMs<sub>PMB</sub> ) with payloads up to 2% that are approximately sevenfold higher than those obtained via hydrophobic ion pairing. Within 6 h P85-SEDDS-dRMs<sub>PMB</sub> and AOT-SEDDS-dRMs<sub>PMB</sub> show no release of PMB in aqueous medium, whereas DODAB-SEDDS-dRMs<sub>PMB</sub> and SL-SEDDS-dRMs<sub>PMB</sub> show a sustained release. DODAB-SEDDS-dRMs<sub>PMB</sub> improves uptake by Caco-2 cells most efficiently reaching even ≈100% within 4 h followed by AOT-SEDDS-dRMs<sub>PMB</sub> with ≈20% and P85-/SL-SEDDS-dRMs<sub>PMB</sub> with ≈5%. The peptide drug maintains its antimicrobial activity in all SEDDS-dRMs<sub>PMB</sub> . According to these results, SEDDS containing dRMs might be a game changing strategy for oral peptide drug delivery."],"journal":["Advanced healthcare materials"],"pagination":["e2302034"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11468804"],"repository":["biostudies-literature"],"pubmed_title":["Self-Emulsifying Drug Delivery Systems (SEDDS) Containing Reverse Micelles: Advanced Oral Formulations for Therapeutic Peptides."],"pmcid":["PMC11468804"],"pubmed_authors":["Jorgensen AM","Steinbring C","Schmid P","Stengel D","To D","Bernkop-Schnurch A"],"additional_accession":[]},"is_claimable":false,"name":"Self-Emulsifying Drug Delivery Systems (SEDDS) Containing Reverse Micelles: Advanced Oral Formulations for Therapeutic Peptides.","description":"Alternative methods to hydrophobic ion pairing for the formation of lipophilic complexes of peptide drugs to incorporate them in lipid-based nanocarriers such as self-emulsifying drug delivery systems (SEDDS) for oral administration are highly on demand. Such an alternative might be reverse micelles. Within this study, SEDDS containing dry reverse micelles (dRMs<sub>PMB</sub> ) formed with an anionic (sodium docusate; AOT), cationic (dimethyl-dioctadecyl-ammonium bromide; DODAB), amphoteric (soy lecithin; SL), or non-ionic (polysorbate 85; P85) surfactant loaded with the model peptide drug polymyxin B (PMB) are developed. They are characterized regarding size, payload, release kinetics, cellular uptake, and peptide activity. SEDDS exhibit sizes from 22.2 ± 1.7 (AOT-SEDDS-dRMs<sub>PMB</sub> ) to 61.7 ± 3.2 nm (P85-SEDDS-dRMs<sub>PMB</sub> ) with payloads up to 2% that are approximately sevenfold higher than those obtained via hydrophobic ion pairing. Within 6 h P85-SEDDS-dRMs<sub>PMB</sub> and AOT-SEDDS-dRMs<sub>PMB</sub> show no release of PMB in aqueous medium, whereas DODAB-SEDDS-dRMs<sub>PMB</sub> and SL-SEDDS-dRMs<sub>PMB</sub> show a sustained release. DODAB-SEDDS-dRMs<sub>PMB</sub> improves uptake by Caco-2 cells most efficiently reaching even ≈100% within 4 h followed by AOT-SEDDS-dRMs<sub>PMB</sub> with ≈20% and P85-/SL-SEDDS-dRMs<sub>PMB</sub> with ≈5%. The peptide drug maintains its antimicrobial activity in all SEDDS-dRMs<sub>PMB</sub> . According to these results, SEDDS containing dRMs might be a game changing strategy for oral peptide drug delivery.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Dec","modification":"2025-04-04T13:54:52.149Z","creation":"2025-04-04T13:54:52.149Z"},"accession":"S-EPMC11468804","cross_references":{"pubmed":["37696266"],"doi":["10.1002/adhm.202302034"]}}